Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant

16Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

We report the case of an 8 week old infant with fulminant autoimmune haemolytic anaemia refractory to conventional immunomodulating treatment. Massive haemolysis resulted in cardiac decompensation and acute renal failure which necessitated mechanical ventilation and peritoneal dialysis. Rituximab, a chimeric anti-CD20 monoclonal antibody, halted progression of the haemolytic process, but the patient died of acute viral pneumonia and disseminated fungal infection. Earlier introduction of rituximab might have prevented the renal complications. Paediatricians should be aware of this useful therapeutic tool for treatment of refractory autoimmune haemolytic anaemia and balance its use against the risk of potential life threatening infection.

Cite

CITATION STYLE

APA

Ng, P. C., Lee, K. K. M., Lo, A. F. C., Li, C. K., & Fok, T. F. (2003). Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant. Archives of Disease in Childhood, 88(4), 337–339. https://doi.org/10.1136/adc.88.4.337

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free